Both in Biotechnology
Recursion Pharmaceuticals vs Replimune Group
Over the past year RXRX returned −22.4% and REPL returned +130.7%; their daily moves had a correlation of 0.10.
RXRX −22.4% REPL +130.7%Growth of $1, one year, split-adjusted
| Metric | RXRX | REPL |
|---|---|---|
| Price | $3.88 | $20.69 |
| Market cap | $2.32B | $1.96B |
| Today | +5.43% | +0.19% |
| 1 month | −16.2% | +56.2% |
| 6 months | +13.1% | +501.5% |
| Year to date | −5.1% | +112.9% |
| 1 year | −28.7% | — |
| Revenue growth (YoY) | +258.5% | — |
| Gross margin | 45.9% | — |
| Net margin | −641.6% | — |
| P/E (TTM) | — | — |
| Price / sales | 34.0× | — |
| Net cash | $538.0M | $183.7M |
| Dividend yield | — | — |
| Volatility (60d) | 95.9% | 77.7% |
| Short % of float | 37.5% | 29.6% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).